You are leaving GSKSource to visit a separate website not associated with GSKSource, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Source.GSK is not responsible for content on third-party websites.
You must be registered with GSKSource in order to attend an Event/WebinarRequired field
This program will review clinical efficacy and safety data that support the use of LAMA/LABA or triple therapy for appropriate patients with COPD. The program will last approximately 45 minutes and conclude with an optional Q&A.
This program will answer key questions about managing patients with COPD with triple (ICS/LABA/LAMA) therapy. It will review clinical efficacy and safety data that support the use of triple therapy for appropriate patients with COPD. The program will last
PM-US-FVU-WCNT-180028 January 2019
TRELEGY is for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for reducing exacerbations in patients with a history of exacerbations. TRELEGY is NOT indicated for relief of acute bronchospasm or asthma.